Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05555732 · ClinicalTrials.gov registry record · Phase 3

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

A Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by Daiichi Sankyo.

Active
Registry status
Phase 3
Development phase
1,170
Enrollment target
20
Study locations

NCT05555732: Active Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by Daiichi Sankyo.

NCT05555732 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 1,170 participants, above the 345-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (239% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05555732, a Phase 3 study of Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,170 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

Primary Outcome

Progression-free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.

Conditions Studied

Metastatic Non Small Cell Lung Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG Datopotamab Deruxtecan

Study Locations (20)

Florida

  • Florida Cancer Specialists - South - Fort Myers
  • Cancer Specialist of North Florida - Jacksonville
  • Cancer Care Centers of Brevard, Inc. - Palm Bay
  • Woodlands Medical Specialists, Pa - Pensacola
  • Florida Cancer Specialists-North - St. Petersburg

California

  • Hoag Memorial Hospital Prebyterian - Newport Beach
  • Compassionate Cancer Care Medical Group - Riverside
  • Sansum Clinic - Santa Barbara
  • Ronald Reagan UCLA Medical Center - Santa Monica

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute; Inv Drg Svc Pharm - Boston
  • Dana Farber Cancer Institute At St. Elizabeth'S Medical Center - Brighton

Arizona

  • Ironwood Cancer and Research Centers - Chandler
  • Arizona Oncology Associates, Pc - Nahoa - Prescott Valley

Maryland

  • American Oncology Partners of Maryland - Bethesda
  • Maryland Oncology Heamtology P.A. - Columbia

Alabama

  • Southern Cancer Center Pc - Daphne

Colorado

  • UCHealth Memorial Hospital - Colorado Springs

Georgia

  • Emory University - Winship Cancer Institute Wci - Atlanta

Trial Details

FieldValue
Enrollment Target 1,170 participants
Start Date 2023-01-11
Est. Completion 2029-05-11
Phase Phase 3
Daiichi Sankyo

236 total trials

What the registry record for NCT05555732 still lists

NCT05555732 is an interventional study that assigns participants to a tested intervention. Its 1,170 participants enrollment target places it among the larger protocols in the corpus, above the 345-participant average among 31 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (239% higher).

The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT05555732 names 20 study sites across 9 states, led by Florida, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05555732 about?

NCT05555732 is a clinical study titled "Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)". This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell l...

What is the current status of trial NCT05555732?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,170 participants. The study started on 2023-01-11. Estimated completion is 2029-05-11.

What conditions does trial NCT05555732 study?

This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.

What interventions are being tested in trial NCT05555732?

The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Datopotamab Deruxtecan (DRUG).

Who is sponsoring clinical trial NCT05555732?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05555732 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Non Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05555732's enrollment target sits among peer trials

1,170 3rd of 31 higher than 29 of 31 other Metastatic Non Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Non Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06469788 · 1,170 participants · NA

    Testimonials and Navigation in Rheumatology

  • NCT04275557 · 1,174 participants

    Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

  • NCT07009509 · 1,166 participants · NA

    Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping

  • NCT06133322 · 1,176 participants · NA

    Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05555732, the US trial registry maintained by the National Library of Medicine. NCT05555732 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.